The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer

Published:2018-10-29 Issue:5 Volume:37 Page:810-817
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Zhao Huijun,Ma Juan,Lei Ting,Ma Wanru,Zhang Man

Funder

National Key R&D Plan

Beijing Natural Science Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-018-0683-9.pdf

Reference31 articles.

1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. Ca-Cancer J Clin 68(1):7–30

2. Tabayoyong W, Abouassaly R (2015) Prostate Cancer screening and the associated controversy. Surg Clin N Am 95(5):1023–1039

3. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24(19):3089–3094

4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1):33–39

5. Handy CE, Antonarakis ES (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14(10):907–917. https://doi.org/10.2217/fon-2017-0531

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies;Investigational New Drugs;2023-05-17

2. Recent advances in the molecular targeted drugs for prostate cancer;International Urology and Nephrology;2023-01-31

3. Bispecific Antibodies in Targeted Cancer Immunotherapy;Handbook of Cancer and Immunology;2023

4. Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer;Cancers;2022-03-19

5. Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer;Frontiers in Oncology;2021-09-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3